We expect investors to focus on the sales numbers of CRISPR Therapeutics’ CRSP sole-marketed product, Casgevy, and other ...

Gene therapy developer CRISPR Therapeutics AG (CRSP) is navigating some regulatory and commercial dynamics. Its flagship gene ...

Its first approved product, Casgevy, was developed in collaboration with narrow-moat Vertex Pharmaceuticals to treat transfusion-dependent beta-thalassemia (TDT) and sickle-cell disease (SCD).

As biotech investors know, companies in the industry can sometimes earn significant returns in relatively short periods, like a year, thanks to excellent clinical or regulatory progress. Read on to ...

The FDA has lost no time in approving Vertex Pharma and CRISPR Therapeutics pioneering gene-editing therapy Casgevy for its second use, approving the drug for transfusion-dependent beta ...

Gene editing company ToolGen “seeks fair licensing agreement” for alleged infringement by rival | High-value sickle cell ...

ToolGen files patent infringement lawsuit against Vertex Pharma in UK for genome editing therapy CASGEVY: Seoul, South Korea Tuesday, April 22, 2025, 15:00 Hrs [IST] ToolGen, Inc.

The past year has been transformative for Vertex, marked by the launch of Casgevy, a groundbreaking treatment for sickle cell disease patients. This one-time, gene-edited cell therapy, developed ...

We expect investors to focus on the sales numbers of CRISPR Therapeutics’ CRSP sole-marketed product, Casgevy, and other pipeline updates when it reports first-quarter 2025 results. The Zacks ...